Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia & Xgeva in the U.S., Europe, and UK
Under the agreement, Dr. Reddy’s gets exclusive commercialization rights in the United States as well as semi-exclusive rights in Europe and United Kingdom, and Alvotech will be responsible for development and manufacture of the product.